Learn more about Peter Attia’s digital program
#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
The straight dope on cholesterol – Part VI
In this post we’ll address the following concept: Why is it necessary to measure LDL-P, instead of just LDL-C?
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
The straight dope on cholesterol – Part IX
In this post we’ll address the following concept: What should you eat to have the greatest chance of delaying the arrival of cardiovascular disease?
Does low cholesterol cause cognitive impairment? Part II
Safety of lipid-lowering therapy
Low LDL cholesterol and neural development
Why LDL-lowering treatments don’t pit head against heart
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
#83 – Bill Harris, Ph.D.: Omega-3 fatty acids
“I don’t think [omega-6] is the evil that people think it is. The problem is that we need to get more EPA and DHA in our diet, not necessarily get all hung up on omega-6.” — Bill Harris
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.